2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Immunology, Autoimmune Disorders, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

2347 Global analysis of CD28-, 4-1BB-, and LAT-dependent signaling reveals distinct metabolic programs in CAR T cells

Catherine Danis, PhD, Etienne Danis, PhD2, Joshua Michlin, MS3, Travis Nemkov4, Amanda Novak, BS5, M. Eric Kohler, MD, PhD6
1 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
2 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
3 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
4 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
5 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
6 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Despite the upfront success of chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), durable responses remain limited by CAR T-cell dysfunction and poor persistence. Cellular metabolism is a critical determinant of CAR T-cell function and survival, yet how various CAR molecules regulate metabolic programming remains poorly understood. The signaling properties of CD28- and 4-1BB-based CARs not only elicit differences in the kinetics, function, and survival of CAR T-cells, but also drive distinct differences in cellular metabolism. Next-generation CAR constructs incorporate a wide variety of signaling machinery to improve CAR T-cell functions and likely alter metabolic programming, however, the mechanisms by which they regulate metabolism are poorly understood. The Linker for Activation of T cells (LAT) plays a central role in T-cell signaling, yet its contribution to metabolic regulation in conventional and CAR T-cells has not been defined. We recently developed the Adjunctive LAT-Activating CAR T (ALA-CART) platform, which enhances LAT signaling, antigen sensitivity, and persistence. Interestingly, ALA-CART cells demonstrated evidence of enhanced mitochondrial function, suggesting that increasing signaling through the T-cell signalosome can shape CAR T-cell metabolism.

 To define the metabolic consequences of distinct CAR signaling domains, we performed paired metabolomic and transcriptomic analyses of CD22 CAR T cells expressing either a CD28 (22-28ζ) or 4-1BB (22BBζ) 2nd generation CAR or the 22ALA-CART platform at baseline (Day 0), following antigen stimulation (Day 2), and at rest post-activation (Day 5). Baseline metabolomic profiling identified distinct metabolic signatures associated with each CAR construct. 22-28ζ CAR T cells were enriched for lipid metabolites, whereas both 22BBζ and 22ALA-CART cells demonstrated increased TCA cycle intermediates, consistent with enhanced mitochondrial function at rest. Following antigen stimulation, 22-28ζ CAR T cells retained higher levels of lipids, whereas 22BBζ CAR T cells preferentially accumulated amino acid and nucleotide biosynthetic intermediates. In contrast, enhanced LAT signaling was associated with enrichment of glucose, taurine/hypotaurine, deoxycarnitine, and γ-glutamyl metabolites, suggesting enhanced metabolic adaptability, redox homeostasis, and mitochondrial activity. During recovery, 22ALA-CART cells demonstrated sustained enrichment of nucleotide monophosphates, NAD+, and TCA cycle intermediates which correlated with increased proliferation. Transcriptomic analysis corroborated these findings, revealing enrichment of oxidative phosphorylation, electron transport chain, and mitochondrial translation pathways, potentially due to increased TFAM activity downstream of the ALA-CART construct.

At baseline, both 2nd generation constructs and the ALA-CART construct drove similar levels of mitochondrial membrane potential. To further define the metabolic programs downstream of each construct, we assessed the dependence of mitochondrial membrane potential on glycolysis and fatty acid oxidation (FAO). ALA-CART cells demonstrated dependence upon both glycolysis and fatty acid metabolism, where as 22BBζ CARs were predominantly dependent upon FAO alone, suggesting enhanced LAT signaling can increase metabolic flexibility to preserve mitochondrial function under stressful conditions. Finally, we investigated whether these metabolic changes were associated with improved mitochondrial content and fitness. Transmission electron microscopy demonstrated similar mitochondrial abundance across CAR platforms post-stimulation but preserved mitochondrial ultrastructure in 22BBζ and 22ALA-CART cells compared with disrupted cristae architecture observed in 22-28ζ CAR T cells.

Collectively, these studies demonstrate that CD28-, 4-1BB-, and LAT-dependent signaling establish distinct metabolic trajectories throughout CAR T-cell activation. Enhanced LAT signaling promotes sustained mitochondrial metabolism together with preservation of nucleotide pools and redox homeostasis, identifying LAT as a previously underappreciated regulator of CAR T-cell metabolic programming. These findings provide new insight into how proximal signaling networks shape CAR T-cell metabolism and establish the ALA-CART platform as a powerful model for defining signaling mechanisms that can inform the design of next-generation CAR T-cell therapies.

Catherine Danis, PhD: No relevant conflicts of interest to declare.